• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

CeNeRx BioPharma

edit

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company’s product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson’s and Alzheimer’s diseases. The company was founded in 2005 and is based in Cary, North Carolina.

Recent Milestones

edit

• 
  CeNeRx BioPharma received $4.6M in Series D funding. (2/3/12)
  Posted 2/3/12 at 3:10am via onbiovc.com
• 
  CeNeRx BioPharma received $13M in Series C funding. (8/13/10)
  Posted 8/13/10 at 5:50pm via cenerx.com
• 
  CeNeRx BioPharma added Mark Baric as President & Director.
  Posted 8/13/10 at 5:50pm
• 
  CeNeRx BioPharma added Barry Brand as CEO & Director.
  Posted 8/13/10 at 5:50pm
• 
  CeNeRx BioPharma added James Free as COO.
  Posted 8/13/10 at 5:50pm
• 
  CeNeRx BioPharma added Artthur M. Pappas as Member of Board.
  Posted 4/28/13 at 2:30am

Videos

Screenshots

edit

Sources

1. CENERX BIOPHARMA COMPLETES $13 MILLION SERIES C FINANCING (cenerx.com) [edit]
2. CeNeRx BioPharma, Inc.: Series D $4.6M (onbiovc.com) [edit]